Inlyta 5 mg film-coated tablets
Sponsors
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting, Rigshospitalet, Centre Hospitalier Universitaire De Bordeaux, Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
Conditions
Advanced solid tumorCancerGastrointestinal Stromal Tumors (GIST)Metastatic renal cell carcinoma (mRCC) with a good or only one adverse prognostic factor intermediate risk per IMDC scoreMultiple myelomaNon-Hodgkin lymphomaT-cell prolymphocytic leukemiarenal cell carcinoma
Phase 2
A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial)
RecruitingCTIS2023-509152-33-00
Start: 2016-07-25Target: 3000Updated: 2025-12-19
ProTarget - A Danish Nationwide Clinical Trial on Targeted Anti‐Cancer Treatment based on Genomic Profiling
RecruitingCTIS2023-510527-29-00
Start: 2020-09-01Target: 600Updated: 2025-04-25
Neoadjuvant AXITINIB plus AVELUMAB for patients with localized RCC and a moderate to high risk of recurrence (N17JAV)
Not yet recruitingCTIS2024-515825-27-00
Target: 40Updated: 2024-07-11
A Phase II, single arm Study of avelumab in combination with Axitinib in Patients with unresectable/metastatic Gastrointestinal Stromal Tumor after failure of standard therapy - AXAGIST
Active, not recruitingCTIS2024-519176-95-00
Start: 2019-05-08Target: 58Updated: 2025-01-13